Blog: ZYMEWORKS INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K) –


On September 12, 2022, Zymeworks Inc. (“Zymeworks”) issued a press release
announcing that it presented preliminary results from Zymeworks’ Phase 1
clinical trial evaluating zanidatamab zovodotin (ZW49) for the treatment of
HER2-positive tumors.

On September 12, 2022, Zymeworks filed this press release with the Canadian
securities regulatory authorities on the System for Electronic Document Analysis
and Retrieval at

A copy of this press release is attached as Exhibit 99.1 hereto.

The information under this Item 7.01 of this Current Report on Form 8-K and
Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed”
for the purposes of Section 18 of the Securities Exchange Act of 1934 (the
“Exchange Act”), or otherwise subject to the liability of that section, nor
shall such information be deemed incorporated by reference in any filing under
the Exchange Act or the Securities Act of 1933, as amended, regardless of the
general incorporation language of such filing, except as shall be expressly set
forth by specific reference in such filing.


(d) Exhibits

  No.     Description

99.1        Press Release dated September 12, 2022.

104       Cover Page Interactive Data File (embedded as Inline XBRL document).


© Edgar Online, source Glimpses

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s